# Regulus search export - Query: `82 FR 7771` - Source type: All - Part: All - Source: All - Status: All - Jurisdiction: All - Collection: All - Incident class: All - Sort: relevance - Date from: Any - Date to: Any - As of: Current corpus - Results: 1 - Exported: 2026-08-23T16:21:55.824Z ## 1. Procedures for Transportation Workplace Drug and Alcohol Testing Programs: Addition of Certain Schedule II Drugs to the Department of Transportation's Drug-Testing Panel and Certain Minor Amendments **Citation:** 82 FR 7771 **Type / status:** rulemaking / proposed **Agency:** Office of the Secretary **Effective / published:** Not stated / 2017-01-23 The Department of Transportation is proposing to amend its drug-testing program regulation to add four opioids (hydrocodone, hydromorphone, oxymorphone, and oxycodone) to its drug-testing panel; add methylenedioxyamphetamine (MDA) as an initial test analyte; and remove methylenedioxyethylamphetamine, (MDEA) as a confirmatory test analyte. The proposed revision of the drug-testing panel is intended to harmonize with the revised Mandatory Guidelines established by the U.S. Department of Health and Human Services for Federal drug-testing programs for urine testing. This proposal also adds clarification to certain drug-testing program provisions where necessary, removes outdated information in the regulations that is no longer needed, and proposes to remove the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. ### Provenance - Official: Yes - Source: - Source ID: `federal-register` - SHA-256: `e09fcf62b3b5ab9bd949aff4dca1a7c0c5a54bf2fd749be3a8df88098964a4a9` - Retrieved: 2026-08-20T06:04:51.294Z - Document slug: `federal-register-2017-01131` - Related records: 38